Safety of medications for cardiovascular diseases in community clinics

doi:10.19803/j.1672-8629.2022.07.10

Abstract

Abstract: Objective To explore the characteristics of adverse drug reactions/adverse drug events (ADR/ADE) caused by drugs for cardiovascular diseases in community clinics and to recommend targeted warning and prevention measures. Methods Using frequency statistics and association rules, 180 cases of ADR/ADE caused by drugs for cardiovascular diseases reported by four community clinics between January 1, 2004 and June 30, 2021 were retrospectively analyzed. Results Patients ages 70 to 79 were the most vulnerable, and intravenous administration was the main route reported. Only 7.78% of the cases had a drug allergy history. Pruritus and rash were the main symptoms. Most of the ADR/ADE related to Chinese and western medicines involved blood lipid modulators and blood-removing agents, while those caused by Chinese medicines involved drugs which were bitter in taste, warm in nature, liver-targeting and contained cinnabar. ADR/ADE were more likely when gastrodin, cinnamazide maleate, theophylline, ambroxol, salvia miltiorrhiza safflower preparation and ginkgo biloba extract were used together. Conclusion Community clinicians should be alert to the influence of patients' age, routes of administration, history of drug allergy, properties of traditional Chinese medicine, toxic drugs, and combination of drugs (traditional Chinese medicine and western medicine) on the incidence of ADR/ADE related to cardiovascular drugs, and strengthen rational use of drugs by whatever means available.

Key words: cardiovascular drugs, community clinicians, drug safety, adverse drug reactions, pharmacovigilance

CLC Number:

R994.1
R972

WANG Juli, ZHANG Xiaomeng, ZHANG Bing, LYU Jintao. Safety of medications for cardiovascular diseases in community clinics[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 744-748.

References

[1] LI J, GAO X, LEI XY, et al.Study on the influencing factors of primary medical institutions for middle-aged and elderly patients with hypertension: based on the data of China health and old-age care tracking survey 2015[J]. Journal of Practical Cardio-Cerebral Pulmonary Vascular Diseases(实用心脑肺血管病杂志), 2020, 28(2): 89-93.
[2] MI Y, ZHU XY, TIAN Y, et al.Study on rational drug use index and prescription behavior in 20 primary medical institutions[J]. Chinese Pharmacy(中国药事), 2017, 31(7): 795-801.
[3] LI A, ZHANG B, ZHANG XM, et al.Investigation on the cognition and reporting of adverse drug reactions in 1109 primary medical institutions[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2017, 14(5): 289-294.
[4] National Medical Products Administration. National adverse drug reaction annual monitoring report(2020 No.105)[EB/OL].(2021-03-06) [2021-12-01]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/gzwj/gzwjyp/20210325170127199.html.
[5] Drug Evaluation Center of China Food and Drug Administration.Handbook of adverse drug reaction reporting and monitoring(药品不良反应报告和监测工作手册)[EB/OL]. (2013-04-26)[2019-10-08]. http://www.cdr-adr.org.cal/was5/wed/search.
[6] LIU W, JIANG HC, YAO JQ, et al.Research on traditional Chinese medicine prescription data based on association rule mining algorithm Apriori[J]. China Computer & Communication (theory edition)[信息与电脑(理论版)], 2020, 32(16): 51-55.
[7] DI N, ZHENG JT, WANG PF, et al.Analysis of chronic diseases and comorbidities among elderly in Beijing[J]. Chinese General Practice(中国全科医学), 2018, 21(3): 265-268.
[8] ZHOU WL, ZHANG XM, ZHANG B.Safety analysis and warning thinking of TCM decoction pieces for promoting blood circulation and removing stasis[J]. China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志), 2016, 31(11): 4637-4643.
[9] National Center for ADR Monitoring, China. Annual Report for National ADR Monitoring (2020)[EB/OL]. (2021-03-26)[2022-01-01]. https://www.cdr-adr.org.cn/center_news/202103/t20210326_48413.html.
[10] SA RN, ZHANG B, LIN ZJ, et al.Pharmacovigilance of traditional Chinese medicine in pharmaceutical care in medical institutions[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(5): 422-426.
[11] ZHANG B, LYU JT, ZHANG XM, et al.“Toxic-effect”cognition and pharmacovigilance thinking of traditional Chinese medicine based on“property”[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(5): 411-415.
[12] Beijing Association of Cerebrovascular Disease Prevention and Treatment, expert consensus writing group of gastrodin preparation clinical application. Chinese expert consensus on clinical application of gastrodin preparation (2021)[J]. Chinese Journal of Geriatrics(中华老年医学杂志), 2021,40(4):407-415.
[13] GAO Y, LIU M, SHI SZ, et al.Systematic evaluation and reevaluation of Shuxuening injection[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2021, 46(14): 3712-3721.
[14] YU YQ, SHI DZ, QU H, et al.Treatment of unstable angina pectoris with Huoxue huayu traditional Chinese medicine injection: a meta-analysis[J]. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease(中西医结合心脑血管病杂志), 2021, 19(17): 2893-2903.
[15] DU J, YANG W, YI DH, et al.Analysis of combined medication of Danhong injection in treatment of coronary heart disease based on HIS “real world”[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2011, 36(20): 2821-2824.
[16] LI YL, ZHANG B, ZHANG XM, et al.Clinical safety evaluation and thinking of traditional Chinese medicine based on toxic ingredients[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(6): 520-524.
[17] RAN C.Signal mining and risk factors analysis of adverse reaction of iodine contrast agent[D]. Chongqing Medical University, 2020.
[18] ZHANG D, LYU JT, ZHANG B, et al.Construction and application of "four- dimens ional linkage" research platform for pharmac-ovigilance of traditional Chinese medicine[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(5): 416-421.
[19] ZHANG XM, ZHANG B, ZHANG D, et al.Study on the risk and benefit threshold of the clinical application of traditional Chinese medicine with toxicities of simbic fever[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(6): 514-519, 524.